157 related articles for article (PubMed ID: 22032837)
1. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
Chon HS; Marchion DC; Xiong Y; Chen N; Bicaku E; Stickles XB; Bou Zgheib N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Lancaster JM
Gynecol Oncol; 2012 Jan; 124(1):119-24. PubMed ID: 22032837
[TBL] [Abstract][Full Text] [Related]
2. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
Marchion DC; Cottrill HM; Xiong Y; Chen N; Bicaku E; Fulp WJ; Bansal N; Chon HS; Stickles XB; Kamath SG; Hakam A; Li L; Su D; Moreno C; Judson PL; Berchuck A; Wenham RM; Apte SM; Gonzalez-Bosquet J; Bloom GC; Eschrich SA; Sebti S; Chen DT; Lancaster JM
Clin Cancer Res; 2011 Oct; 17(19):6356-66. PubMed ID: 21849418
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
[TBL] [Abstract][Full Text] [Related]
4. AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.
Gray MJ; Mhawech-Fauceglia P; Yoo E; Yang W; Wu E; Lee AS; Lin YG
Int J Cancer; 2013 Jul; 133(1):21-30. PubMed ID: 23280503
[TBL] [Abstract][Full Text] [Related]
5. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of
Roh JW; Choi JE; Han HD; Hu W; Matsuo K; Nishimura M; Lee JS; Kwon SY; Cho CH; Kim J; Coleman RL; Lopez-Bernstein G; Sood AK
Cancer Biol Ther; 2020; 21(2):147-156. PubMed ID: 31640461
[TBL] [Abstract][Full Text] [Related]
7. BAD-mediated apoptotic pathway is associated with human cancer development.
Stickles XB; Marchion DC; Bicaku E; Al Sawah E; Abbasi F; Xiong Y; Bou Zgheib N; Boac BM; Orr BC; Judson PL; Berry A; Hakam A; Wenham RM; Apte SM; Berglund AE; Lancaster JM
Int J Mol Med; 2015 Apr; 35(4):1081-7. PubMed ID: 25653146
[TBL] [Abstract][Full Text] [Related]
8. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of leukemia inhibitory factor enhances chemotherapy tolerance of endometrial cancer cells
Ruan X; Zhong M; Liu W; Liu Q; Lu W; Zheng Y; Zhang X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jan; 40(1):20-26. PubMed ID: 32376564
[TBL] [Abstract][Full Text] [Related]
10. Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance.
Ding N; Zhang H; Su S; Ding Y; Yu X; Tang Y; Wang Q; Liu P
Anticancer Agents Med Chem; 2018; 18(7):1054-1063. PubMed ID: 29256357
[TBL] [Abstract][Full Text] [Related]
11. PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells.
Wan X; Li J; Xie X; Lu W
Int J Gynecol Cancer; 2007; 17(4):808-12. PubMed ID: 17359293
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells.
Girouard J; Lafleur MJ; Parent S; Leblanc V; Asselin E
Gynecol Oncol; 2013 Feb; 128(2):335-43. PubMed ID: 23174537
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
Zhao N; Guo Y; Liu P; Chen Y; Wang Y
Arch Gynecol Obstet; 2022 Mar; 305(3):693-701. PubMed ID: 34476599
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway.
Kong C; Zhu Z; Li Y; Xue P; Chen L
Clin Transl Oncol; 2021 Jul; 23(7):1334-1341. PubMed ID: 33515421
[TBL] [Abstract][Full Text] [Related]
15. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin.
Indermaur MD; Xiong Y; Kamath SG; Boren T; Hakam A; Wenham RM; Apte SM; Lancaster JM
Am J Obstet Gynecol; 2010 Aug; 203(2):158.e1-40. PubMed ID: 20444440
[TBL] [Abstract][Full Text] [Related]
16. Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.
Sastry KS; Chouchane AI; Wang E; Kulik G; Marincola FM; Chouchane L
Cell Death Dis; 2017 Jun; 8(6):e2844. PubMed ID: 28569785
[TBL] [Abstract][Full Text] [Related]
17. GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer.
Luvsandagva B; Nakamura K; Kitahara Y; Aoki H; Murata T; Ikeda S; Minegishi T
Gynecol Oncol; 2012 Jul; 126(1):132-9. PubMed ID: 22543280
[TBL] [Abstract][Full Text] [Related]
18. Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
Yang B; Ke W; Wan Y; Li T
Biochem Biophys Res Commun; 2021 Mar; 545():89-97. PubMed ID: 33548629
[TBL] [Abstract][Full Text] [Related]
19. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.
Bansal N; Marchion DC; Bicaku E; Xiong Y; Chen N; Stickles XB; Sawah EA; Wenham RM; Apte SM; Gonzalez-Bosquet J; Judson PL; Hakam A; Lancaster JM
J Gynecol Oncol; 2012 Jan; 23(1):35-42. PubMed ID: 22355465
[TBL] [Abstract][Full Text] [Related]
20. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
